story of the week
Canagliflozin May Reduce Cardiovascular Events in Type 2 Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
N. Engl. J. Med 2017 Jun 12;[EPub Ahead of Print], B Neal, V Perkovic, KW Mahaffey, D de Zeeuw, G Fulcher, N Erondu, W Shaw, G Law, M Desai, DR Matthews,From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.